An Open Label, Phase 1b Rollover Study to Assess the Long-Term Safety Profile of Lapatinib (GW572016) in Cancer Patients.
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the long-term safety and tolerability of lapatinib as monotherapy or in combination regimen
Ongoing study until the new lapatinib rollover study, EGF111767, is approved at the current sites.
GSK Clinical Trials
Israel: Ministry of Health
|GSK Investigational Site||Indianapolis, Indiana 46260|
|GSK Investigational Site||Albuquerque, New Mexico 87109|
|GSK Investigational Site||Raleigh, North Carolina 27609|
|GSK Investigational Site||Akron, Ohio 44304|
|GSK Investigational Site||Fort Worth, Texas 76104|
|GSK Investigational Site||Hooksett, New Hampshire 03106|
|GSK Investigational Site||Pittsburgh, Pennsylvania 15213|
|GSK Investigational Site||Germantown, Tennessee 38138|